Health
FDA warns GLP-1 weight loss medications can cause rare blindness-causing eye condition.
FDA reviewed 126 trials and found 15 probable NAION cases, with rates higher among users than controls.
OriginalSourceGlobal NewsCanadaOwner: Global Television NetworkLeanUnratedCredibilityUnratedPublished18:17 UTCSourceGlobal NewsCanadaOwner: Global Television NetworkLeanUnratedCredibilityUnratedPublished18:17 UTC
“FDA to require vision loss warning on GLP-1 drug labels”
“The labelling requirement stems from the findings of a 2024 study and subsequent FDA trials that tested the results of that study.”
FDA to require NAION vision loss warning on GLP-1 labels
Key points
- FDA will mandatorily add NAION risk to all GLP-1 drug labels.
- Risk stems from a 2024 study and FDA trials reviewed by regulators.
- NAION is a painless condition causing potential permanent vision loss.
- Roughly 6 per 100,000 GLP-1 users for at least one year affected.
- Canada also reviewed Ozempic, Rybelsus, Wegovy for NAION risk.
Other reports
- SourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS NewsSourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS News
“FDA warns of rare vision-loss side effect from GLP-1 drugs”
- SourceMintIndiaOwner: HT MediaLeanCenterCredibilityRatings: AllSides, MBFCRead at MintSourceMintIndiaOwner: HT MediaLeanCenterCredibilityRatings: AllSides, MBFCRead at Mint
- SourceArs TechnicaUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at Ars TechnicaSourceArs TechnicaUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at Ars Technica
“GLP-1 drugs may increase risk of vision loss from rare condition, FDA warns”
- SourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The IndependentSourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Independent
- SourceThe NationalUnited Arab EmiratesLeanUnratedCredibilityUnratedRead at The NationalSourceThe NationalUnited Arab EmiratesLeanUnratedCredibilityUnratedRead at The National
“FDA orders new warning on GLP-1 drugs over potential risk of blindness”
- SourceBBCUnited KingdomOwner: British Broadcasting CorporationLeanCenterCredibilityRatings: AllSides, MBFCRead at BBCSourceBBCUnited KingdomOwner: British Broadcasting CorporationLeanCenterCredibilityRatings: AllSides, MBFCRead at BBC
“Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness”
- SourceThe GuardianUnited KingdomOwner: Guardian Media GroupLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The GuardianSourceThe GuardianUnited KingdomOwner: Guardian Media GroupLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Guardian
“FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications”
- SourceBusinessLineIndiaLeanUnratedCredibilityUnratedRead at BusinessLineSourceBusinessLineIndiaLeanUnratedCredibilityUnratedRead at BusinessLine
“FDA flags possible risk of rare eye condition with GLP-1 drugs, orders new safety warning”
How it got here
Global News publishes the article.
concise.news reads it.
Grouped with 8 other reports as story 8.
The Brief ranks it 8th.
8 8 FDA warns GLP-1 weight loss medications can cause rare blindness-causing eye condition.
FDA reviewed 126 trials and found 15 probable NAION cases, with rates higher among users than controls.